AOD-9604 is not an authorized pharmaceutical ingredient in Canada, and Health Canada has confirmed that unauthorized peptides cannot lawfully be compounded for human use
Use a Precise Syringe: Use a high-quality insulin syringe with clear markings
Data availability The atomic coordinates and electron microscopy maps have been deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under accession codes: 9BP3/EMD-44760 [ (Cagri-AMY 1 R-DNG s complex), 9BLW/EMD-44678 [ (CagriBB-AMY 1 R-DNG s complex), 9BQ3/EMD-44796 [ (Cagri-AMY 2 R-DNG s complex), 9BTW]/EMD-44898 [ (Cagri-AMY 3 R-DNG s complex), 9BUB/EMD-44904 [ (Cagri-CTR-DNG s complex 1, bypass conformation), 9BUD/EMD-44906 [ (Cagri-CTR-DNG s complex 1, CT-like conformation), 9BUC/EMD-44905 [ (Cagri-CTR-DNG s complex 2, bypass conformation), 9BUE/EMD-44907 [ (Cagri-CTR-DNG s complex 2, CT-like conformation), 9BLC/EMD-44653 [ (CagriBB-CTR-DNG s complex 1, CT-like conformation), 9BLB/EMD-44652 [ (CagriBB-CTR-DNG s complex 1, bypass conformation)
AOD 9604 (Anti-Obesity Drug 9604) is a modified derivative of HGH Fragment 176-191, originally developed by an Australian pharmaceutical company as a candidate compound for obesity research
The maintenance dose can be 1.7 mg or 2.5 mg weekly
